All JIA patients Median (IQR) or Number (%) | |
---|---|
Gender, female | 331 (75%) |
Age at treatment start, years | 33 (24–41) |
Age at disease onset, years | 13 (9–15) |
Disease duration, years | 22 (13–31) |
Ethnicity; white | 338 (95%) N=356 |
On methotrexate | 257 (58%) |
On steroids | 173 (39%) |
Disease pattern | |
Systemic onset | 12 (3%) |
Oligoarticular pattern | 7 (2%) |
Polyarticular pattern | 327 (73%)* |
Enthesitis-related arthritis | 53 (12%) |
Psoriatic arthritis | 44 (10%) |
TNFi at registration | |
Etanercept | 199 (45%) |
Infliximab | 137 (31%) |
Adalimumab | 101 (23%) |
Certolizumab | 6 (1%) |
Disease activity | |
28 tender joint count | 14 (8–20) N=401 |
28 swollen joint count | 10 (5–15) N=402 |
Patient global assessment (100 mm VAS) | 75 (65–85) N=405 |
ESR, mm/hour | 35 (19–56) N=402 |
CRP, mg/L | 30 (10–52) N=210 |
DAS28 | 6.2 (5.5–7.0) N=405 |
HAQ (0–3) | 1.9 (1.5–2.4) N=403 |
Total comorbidities† | N=423 |
None | 227 (54%) |
1 | 131 (31%) |
≥2 | 65 (15%) |
Smoking status | N=438 |
Current smoker | 101 (23%) |
Previous smoker | 79 (18%) |
Never smoked | 258 (59%) |
*150 patients with polyarticular pattern were rheumatoid factor positive (46% of polyarticular pattern, 33% of cohort overall).
†Comorbidities include; hypertension, angina, myocardial infarction, stroke, epilepsy, asthma, chronic bronchitis/emphysema, peptic ulcer, liver disease, renal disease, tuberculosis, demyelination, diabetes, hyperthyroidism, depression, cancer.
Presenting number (%), or median (IQR), including number with available data (N) where applicable.
CRP, C reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; JIA, juvenile idiopathic arthritis; TNFi, tumour necrosis factor inhibitor; VAS, visual analog scale.